Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Haller

Showing results (291-300 of 395) with videos related to

Pageof 40
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancerDaniel G Haller, Josep Tabernero, Jean Maroun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.
Brain : a Journal of Neurology|November 6, 2008
Resistance training in patients with single, large-scale deletions of mitochondrial DNAJulie L Murphy, Emma L Blakely, Andrew M Schaefer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancerRamesh K Ramanathan, Jeffery W Clark, Nancy E Kemeny, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1993
Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinomaL M Weiner, E Harvey, K Padavic-Shaller, et al.
Clinical Colorectal Cancer|January 27, 2010
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008Timothy J Price, Niall C Tebbutt, Christos S Karapetis, et al.
The American Journal of Gastroenterology|September 25, 2001
Long term survival after pancreatic resection for pancreatic adenocarcinomaN A Ahmad, J D Lewis, G G Ginsberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III TrialHans-Joachim Schmoll, Josep Tabernero, Jean Maroun, et al.
The Journal of Clinical Investigation|October 1, 1991
Deficiency of skeletal muscle succinate dehydrogenase and aconitase. Pathophysiology of exercise in a novel human muscle oxidative defectR G Haller, K G Henriksson, L Jorfeldt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 daysWeijing Sun, James P Stevenson, Maryann L Gallagher, et al.
Pageof 40

Showing results (291-300 of 395) with videos related to

Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancerDaniel G Haller, Josep Tabernero, Jean Maroun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.
Brain : a Journal of Neurology|November 6, 2008
Resistance training in patients with single, large-scale deletions of mitochondrial DNAJulie L Murphy, Emma L Blakely, Andrew M Schaefer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancerRamesh K Ramanathan, Jeffery W Clark, Nancy E Kemeny, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1993
Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinomaL M Weiner, E Harvey, K Padavic-Shaller, et al.
Clinical Colorectal Cancer|January 27, 2010
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008Timothy J Price, Niall C Tebbutt, Christos S Karapetis, et al.
The American Journal of Gastroenterology|September 25, 2001
Long term survival after pancreatic resection for pancreatic adenocarcinomaN A Ahmad, J D Lewis, G G Ginsberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III TrialHans-Joachim Schmoll, Josep Tabernero, Jean Maroun, et al.
The Journal of Clinical Investigation|October 1, 1991
Deficiency of skeletal muscle succinate dehydrogenase and aconitase. Pathophysiology of exercise in a novel human muscle oxidative defectR G Haller, K G Henriksson, L Jorfeldt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 daysWeijing Sun, James P Stevenson, Maryann L Gallagher, et al.
Pageof 40